| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 3, 2026Next | Q2 2027 | — | 2.71 | 1.58 B |
Sep 1, 2026
Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026. Dan Carestio, President and CEO of STERIS will present at 1:05 p.m. Eastern Time. A simultaneous webcast and replay of the Company’s presentation will be available on STERIS’s investor relations website at www.steris-ir.com. About STERIS STERIS is a leading globa
Aug 28, 2026
An official report on August 27, 2026 reveals Representative Jared Moskowitz's recent sale of Steris (NYSE:STE) stock, valued between $2,002 and $30,000. The transaction took place on July 13, 2026, as per the
Aug 26, 2026
STERIS has lagged behind the broader market over the past year, and analysts remain somewhat bullish about the stock’s prospects.
Aug 21, 2026
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
Aug 20, 2026
STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
Aug 19, 2026
Over the past six months, STERIS’s shares (currently trading at $232.53) have posted a disappointing 7.4% loss, well below the S&P 500’s 12.9% gain. This might have investors contemplating their next move.
Aug 18, 2026
STERIS PLC passes quality investing screens with 25.28% ROIC, strong growth, and excellent cash conversion, making it a standout long-term compounder.
Aug 17, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q2, starting with STERIS (NYSE:STE).
Aug 9, 2026
STERIS (NYSE:STE) reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina. Total reported revenue increased 7% from th
Aug 7, 2026
UBS analyst Patrick Wood maintains Steris (NYSE:STE) with a Buy and lowers the price target from $275 to $270.
Piper Sandler analyst Jason Bednar reiterates Steris (NYSE:STE) with a Overweight and raises the price target from $270 to $275.
Aug 6, 2026
STERIS plc (STE) Q1 2027 Earnings Call August 6, 2026 9:00 AM EDTCompany ParticipantsJulie Winter - Vice President of Investor Relations & Corporate...
STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.
Recent dividend hikes from DRH, STE, BCC, KWR and WHD highlight financially solid companies as investors seek stability in a mixed market.
The Dublin-based company plans to relocate some existing U.S. operations to the new 600,000-square-foot campus in the coming years.
The mystery behind “Project Sol” has been revealed. Global healthcare company STERIS will build a $600 million manufacturing, research and distribution campus in Sanford, bringing at least 335 jobs to Lee County in what local leaders say is the largest economic development project in the county’s history. Gov. Josh Stein, and the Sanford Area Growth Alliance, announced Wednesday that STERIS ...
STERIS plc recently announced plans to invest US$600 million in its largest-ever manufacturing project, a 600,000 square-foot formulated chemistries Center of Excellence in North Carolina that will consolidate production and distribution and create about 335 jobs, while also increasing its quarterly dividend to US$0.69 per share for a 21st year of growth. The combination of solid fiscal 2027 first-quarter revenue growth, reaffirmed full-year guidance, and this major North Carolina...
Aug 5, 2026
STERIS (STE) has drawn fresh attention after committing US$600 million to a new formulated chemistries Center of Excellence in North Carolina, a major manufacturing shift that consolidates production and distribution on a single campus. See our latest analysis for STERIS. Against this backdrop, STERIS shares have risen 9.11% over the past month and 8.90% over the past quarter. The 1 year total shareholder return of 6.32% points to steadier long term compounding and suggests recent momentum...
While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Medical equipment and services company Steris (NYSE:STE) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 7.3% year on year to $1.49 billion. Its non-GAAP profit of $2.59 per share was 3.9% above analysts’ consensus estimates.
STERIS beats Q1 EPS, revenue slightly misses; FY guidance steady, capex raised, shares dip ~1.2%.
Steris (STE) delivered earnings and revenue surprises of +1.97% and -0.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59Targeted restructuring plan announced associated with new Formulated Chemistries Center of Excellence in North Carolina DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first qua
Steris (NYSE:STE) affirms FY2027 GAAP EPS guidance from $9.00-$9.20 to $9.00-$9.20 vs $9.08 analyst estimate..
Steris (NYSE:STE) widens FY2027 Adj EPS guidance from $11.10-$11.30 to $11.00-$11.30 vs $11.16 analyst estimate. Affirms FY2027 sales outlook from $6.352 billion-$6.411 billion to $6.352 billion-$6.411 billion vs $6.371
